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Abstract
Previously, bifunctional peptide inhibitors (BPI) with a single antigenic peptide have been shown
to suppress experimental autoimmune encephalomyelitis (EAE) in an antigen-specific manner. In
this study, a multivalent BPI (MVBMOG/PLP) with two antigenic peptides derived from myelin
oligodendrocyte glycoprotein (MOG38-50) and myelin proteolipid protein (PLP139-151) was
evaluated in suppressing MOG38-50- and PLP139-151-induced EAE. MVBMOG/PLP significantly
suppressed both models of EAE even when there was some evidence of epitope spreading in the
MOG38-50-induced EAE model. In addition, MVBMOG/PLP was found to be more effective than
PLP-BPI and MOG-BPI in suppressing MOG38-50-induced EAE. Thus, the development of MVB
molecules with broader antigenic targets can lead to suppression of epitope spreading in EAE.
Keywords
Experimental autoimmune encephalomyelitis; Bifunctional peptide inhibitor; Antigen-presenting
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1. Introduction
Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease of the central
nervous system (CNS). The pathogenesis of MS has not been fully elucidated; however, it is
categorized as a CD4+ T cell-mediated autoimmune disease (Bielekova et al., 1999, Zhang
et al., 1994). It is thought that there is a breakdown in the recognition of self versus non-self
antigens, and that the immune system starts recognizing protein components of the myelin
sheath as antigens. Major immunodominant proteins of the myelin sheath are myelin
proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), and myelin basic
protein (MBP). During disease, T cells can recognize epitopes of these proteins and initiate
an inflammatory immune response toward them, leading to tissue damage. The debris from
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the broken down tissue leads to epitope spreading, thus resulting in new tissue components
becoming antigenic (Vanderlugt and Miller, 1996).
An animal model known as experimental autoimmune encephalomyelitis (EAE) is often
used to study MS. This model mimics some of the pathological features of MS such as CNS
inflammation, lesion formation, blood-brain barrier (BBB) breakdown, and the presence of
myelin-specific CD4+ T cells (Lassmann, 2001, Voskuhl et al., 1993). In addition, the
animal model can be used to study the epitope spreading process (Tuohy and Kinkel, 2000).
Unlike MS, however, EAE has an initiating antigen that can be controlled by injection of the
encephalotogenic peptide in the presence of complete Freund's adjuvant (CFA). This is a
powerful tool because therapies can be developed to specifically suppress the immune
response to these antigens. Antigen-specific immunotherapy has become widely investigated
recently with the aim of inducing tolerance to specific antigens; therefore, it attenuates the
inflammatory response. Previously in our laboratory, bifunctional peptide inhibitors (BPI)
composed of antigenic peptides conjugated to adhesion peptides have been developed and
have successfully suppressed EAE (Kobayashi et al., 2007, Kobayashi et al., 2008, Ridwan
et al., 2010, Zhao et al., 2010, Manikwar et al., 2011). BPI molecules contain a specific
antigen (i.e., PLP) and have been shown to suppress EAE induced by a specific antigen (i.e.,
PLP). Therefore, they will not be useful for suppressing EAE generated by a different
antigen (i.e., MOG or MBP). In addition, antigen-specific modulation may not solve the
problem of epitope spreading when the disease is in its late stage. Therefore, a new kind of
BPI molecule known as multivalent BPI (MVB) has been designed with more than one
antigen. The goal is that the MVB molecule will modulate the immune response to suppress
the disease regardless of the inciting antigen, thus solving the problem of epitope spreading
and making this strategy more applicable for translation into a MS therapy.
In EAE and MS, the activation of inflammatory CD4+ T cells is mediated by two signalsthat
are delivered from antigen-presenting cells (APC) to T cells (Grakoui et al., 1999, Tseng and
Dustin, 2002). The first signal (Signal 1) is the antigen presentation by the major
histocompatibility complex class-II (MHC-II) molecule, which is recognized by the T-cell
receptor (TCR). The second signal (Signal 2) is made up of costimulatory and adhesion
molecules on both APC and T cells. After the molecular pair interactions form both signals,
signal translocation occurs to form the immunological synapse that leads to activation of a
sub-population of antigen-specific T cells (Lee et al., 2002, van der Merwe, 2002). The
hypothesis is that BPI molecules are designed to simultaneously target Signal 1 and
adhesion molecules on the surface of APC to hinder the formation of the immunological
synapse, which will prevent the activation of the inflammatory T cells that specifically
recognize the antigenic portion of the BPI molecule. MVB molecules are composed of more
than one antigenic peptide, and can therefore bind to different MHC-II molecules on the
same or different APC. Thus, the inflammatory response toward more than one antigen is
prevented.
In this study, MVB comprised of MOG38-50 and PLP139-151 (MVBMOG/PLP) was developed
and evaluated for suppressing two different antigen-induced EAE models. As controls,
MOG-BPI and PLP-BPI were evaluated for cross-reactivity in MOG-induced and PLP-
induced EAE. In this case, the efficacy of MOG-BPI was evaluated in PLP-induced EAE,
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and the efficacy of PLP-BPI was evaluated in MOG-induced EAE. Finally, some
mechanistic aspects of MVB were elucidated by determining the cytokines produced by
splenocytes of the EAE animals upon treatment.
2. Materials and Methods
2.1. Mice
All protocols for experiments involving SJL/J (H-2s) (Charles River, Wilmington, MA) and
C57BL/6 (Jackson Laboratory, Bar Harbor, ME) were approved by the University's
Institutional Animal Care and Use Committee. The mice were housed under specific
pathogen-free conditions at a facility at the University of Kansas, which is approved by the
Association for Assessment and Accreditation of Laboratory Animal Care.
2.2. Peptide Synthesis
Peptides used in this study are listed in Table 1. 9-Fluorenylmethyloxy-carbonyl-protected
amino acid chemistry was used to synthesize all peptides, utilizing an appropriate PEG-PS™
resin (Applied Biosystems, Foster City, CA) in an automated peptide synthesis system
(Pioneer™:PerSeptive Biosystems, Framingham, MA). The peptides were cleaved from the
resin, and removal of the protecting groups from the side-chain was accomplished with 90%
TFA with 10% scavenger reagents (1,2-ethane dithiol (3%), anisole (2%), and thioanisole
(5%)). The crude products were purified by reversed-phase HPLC using a semi-preparative
C18 column with a gradient of solvent A (95%/5% = H2O (0.1% TFA)/acetonitrile) and
solvent B (100% acetonitrile). Analytical HPLC with a C18 column was used to determine
the purity of each peptide. The identity of each synthesized peptide was confirmed by
electrospray ionization mass spectrometry.
2.3. Induction of EAE and Clinical Evaluation
For the PLP-induced EAE, SJL/J female mice (5–7 weeks old) were immunized
subcutaneously (s.c.) with 200 μg of PLP139-151 peptide in a 0.2 ml emulsion comprised of
equal volumes of phosphate-buffered saline (PBS) solution and CFA containing killed
mycobacterium tuberculosis strain H37RA at a final concentration of 4 mg/ml (Difco,
Detroit, MI). The PLP/CFA emulsion was administered to regions above the shoulder and
the flanks (total of 4 sites; 50 μl at each injection site). In addition, 200 ng of pertussis toxin
(List Biological Laboratories, Campbell, CA) was injected intraperitoneally (i.p.) on the day
of immunization (day 0) and 48 h post-immunization.
For the MOG-induced EAE, C57BL/6 mice (4–6 weeks old) were immunized in a fashion
similar to that mentioned above, except that 200 μg of MOG38-50 peptide was used and 400
ng/mouse/injection of pertussis toxin was administered on days 0 and 2. The clinical scores
that reflect the disease progression were determined by the same observer in a blinded
fashion using a scale ranging from 0 to 5 as follows: 0 - no clinical symptoms, 1 - limp tail
or waddling gait with tail tonicity; 2 - waddling gait with limp tail (ataxia); 2.5 - ataxia with
partial paralysis of one limb; 3 - full paralysis of one limb; 3.5 - full paralysis of one limb
with partial paralysis of the second limb; 4 - full paralysis of two limbs; 4.5 - full paralysis
Badawi and Siahaan Page 3






















of two limbs with partial paralysis of forelimbs; 5 - moribund or dead. Body weight was also
measured daily.
2.4. In vivo Peptide Treatments
Study I - Cross reactivity of MOG-BPI and PLP-BPI—This study was performed to
study the in vivo cross-reactivity of MOG-BPI and PLP-BPI in suppressing EAE. This was
achieved upon induction of the disease with one antigen followed by treating the animals
with a BPI molecule containing another antigen. As positive controls, the in vivo efficacies
of MOG-BPI and PLP-BPI were evaluated to suppress MOG- and PLP-induced EAE,
respectively. Induction of the disease was performed on day 0 as described in section 2.3. In
the MOG-induced EAE, each mouse received s.c. injections of PLP-BPI and MOG-BPI at a
concentration of 100 nmol/100 μl/injection (in PBS) on days 4, 7, and 10. The efficacies of
both PLP-BPI and MOG-BPI were compared to that of the vehicle (PBS). In the PLP-
induced EAE, MOG-BPI was administered s.c. at a concentration of 100 nmol/100 μl/
injection (in PBS) on days 4, 7, and 10. The efficacy of each peptide was evaluated by
monitoring the clinical score and the change in body weight over a period of 25 days.
Study II - In vivo efficacy of novel MVBMOG/PLP in MOG-induced EAE—The
purpose of this study was to evaluate the in vivo efficacy of the novel MVBMOG/PLP in
suppressing MOG-induced EAE. Mice were immunized with MOG/CFA on day 0 as
described in section 2.3. The first group of mice received three s.c. injections of
MVBMOG/PLP at a concentration of 100 nmol/100 μl (in PBS) on days 4, 7, and 10, and its
efficacy was compared to those of the vehicle (100 μl PBS) and positive controls, MOG
(100 nmol/100 μl) and MOG-BPI (100 nmol/100 μl). The negative (PBS) control and the
positive control were each injected three times on days 4, 7, and 10. The efficacy of each
treatment was evaluated using the clinical score and the change in body weight over a period
of 25 days.
Study III - In vivo efficacy of novel MVBMOG/PLP in PLP-induced EAE—The
efficacy of MVBMOG/PLP was also evaluated in PLP-induced EAE. All mice were
immunized with PLP/CFA on day 0 as described in section 2.3. One group of mice received
three s.c. injections of MVBMOG/PLP at a concentration of 100 nmol/100 μl on days 4, 7, and
10; another group received 100 μl of vehicle (PBS) s.c. on the same days. The efficacy of
the peptide was evaluated by monitoring the clinical score and change in body weight over a
period of 25 days.
2.5. In vitro Inflammatory Cytokine Production Assay
In vitro cytokine assays were performed following a protocol similar to that reported
previously (Youssef et al., 2002). Cytokines produced from MOG-induced C57BL/6 mice
treated with MOG-BPI and MVBMog/plp were measured and compared to that from PBS-
treated mice. EAE was induced by injection of MOG/CFA and pertussis toxin as described
in section 2.3, and mice were treated with PBS (100 μl), MOG-BPI (100 nmol/100 μl/
injection), or MVBmog/plp (100 nmol/100 μl/injection) on days 4, 7, and 10. Spleens were
isolated from three mice from each group on day 30. Single cell suspensions of splenocytes
were harvested by gently mashing the spleen through a cell strainer using the rubber end of a
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1-ml syringe in a petri dish containing serum-free RPMI-1640 supplemented with 10% fetal
bovine serum, 100 U penicillin/100 μg streptomycin, 2 mM L-glutamine, and 50 μM 2-
mercaptoethanol. Red blood cells were lysed using ACK lysis buffer (Invitrogen). The
remaining splenocytes were then washed three times with serum-free RPMI-160 medium
(Cellgro). The cells were then primed with PLP (20 μM) in a 24-well plate (5 × 106 cells/
well). Supernatants of cell cultures were collected for cytokine detection 72 hours later and
stored in a −80 °C freezer until analysis. Secreted IL-6 and IFN-γ were measured by
quantitative ELISA-based Q-PlexTM assay (Quansys Biosciences, Logan, UT).
2.6. Splenocyte Proliferation Assay
A proliferation assay was conducted in SJL/J mice in order to evaluate the cross-reactivity
between MOG and PLP. This was accomplished by isolating splenocytes from three PLP-
induced EAE mice per group on day 30 as described in section 2.5. Splenocytes were
isolated from four different groups. One group consisted of mice that had no EAE induced.
The next three groups were mice treated with PBS (100 μl), PLP-BPI (100 nmol/100 μl/
injection), or MVBMOG/PLP (100 nmol/100 μl/injection) on days 4, 7, and 10. The cells were
cultured and stimulated with PLP (2 μM), MOG (2 μM) or concanavalin A (positive
control). Cells were cultured in a 96-well plate (2 × 105 cells/100 μl/well) for 72 hours.
Cultures were then pulsed overnight with 1 μCi of [3H] thymidine per well. Cells were
harvested onto glass fiber filters using the FilterMate Harvester (PerkinElmer), and the
unincorporated [3H] thymidine was removed by multiple washes according to the procedure
recommended by the manufacturers. The incorporated radioactivity was then counted using
a β-scintillation counter (Microbeta Trilux, PerkinElmer).
2.7. Statistical Analysis
Statistical analysis was done using one-way analysis of variance followed by Fisher's least
significance difference to compare the different parameters, including in vitro cytokine
production, splenocyte proliferation, and values from days 10–25 (unless otherwise stated)
for EAE clinical scores and changes in body weight. All statistical analyses were performed
using StatView software (SAS Institute, Inc., Cary, NC). A p-value of less than 0.05 was
used as the criterion for statistical significance.
3. Results
3.1. Study I - Cross Reactivity of MOG-BPI and PLP-BPI
MOG-BPI's efficacy in suppressing MOG-induced EAE was evaluated for the first time. To
test whether there is cross-reactivity between the different antigens, PLP-BPI was tested for
suppressing MOG-induced EAE. The PBS-treated mice developed very severe EAE with a
high average clinical score of 4.0 and 22.15% loss in body weight compared to the day of
onset of disease. The best suppression was observed in the MOG-BPI-treated mice, with a
significant difference in clinical scores and changes in body weight on days 15–25 compared
to those of the PLP-BPI-treated group (p < 0.01 for clinical score and p < 0.0001 for change
in body weight) and the PBS-treated group (p < 0.0001 for clinical score and change in body
weight). PLP-BPI significantly suppressed MOG-induced EAE on days 15–25 compared to
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PBS as indicated by clinical score (p < 0.01) and change in body weight (p < 0.001) (Fig.
1A and Fig 1B).
For the second part of this study, the efficacy of MOG-BPI was evaluated in suppressing
PLP-induced EAE. The PBS-treated mice exhibited signs of EAE with a maximal clinical
score of 1.67 and a maximal loss in body weight of 13.2%. The MOG-BPI-treated mice
showed similar signs of EAE with a maximal clinical score of 1.5 and a maximal loss in
body weight of 11.69%. There were no significant differences in clinical score (p > 0.05)
between the PBS-treated mice and the MOG-BPI-treated mice (Fig. 1C and Fig. 1D).
3.2. Study II - In vivo Efficacy of Novel MVBMOG/PLP in MOG-Induced EAE
For this study, the efficacy of the novel MVBMOG/PLP peptide was tested in suppressing
MOG-induced EAE and was compared to that in PBS-, MOG-, and MOG-BPI-treated mice.
As expected, PBS-treated mice developed severe EAE with a maximal clinical score of 3.58
and a 24.14% loss in body weight. The greatest suppression of disease was observed in mice
treated with the novel MVBMOG/PLP. Clinical scores from days 15–25 showed significant
suppression in the MVBMOG/PLP-treated mice compared to PBS-, MOG-, and MOG-BPI-
treated mice (Fig. 2A, p < 0.0001). The MVBMOG/PLP-treated group reached a maximal
disease score of only 0.88 and 5.15% loss in body weight. Similarly, the change in body
weight of MVBMOG/PLP-treated mice on days 15–25 showed significant differences
compared to those of PBS-, MOG-, and MOG-BPI-treated mice (Fig. 2B, p < 0.0001).
Treatment with MOG-BPI delayed onset of disease by four days. The clinical scores and
loss in body weight indicated that it suppressed disease significantly compared to PBS (p <
0.0001). Clinical scores indicated that MOG-BPI was significantly more efficacious than
MOG peptide (p < 0.05, days 15–25); however, there was no significant difference in the
change of body weight between MOG-BPI- and MOG-treated mice. Compared to PBS-
treated mice, the MOG-treated mice showed significant suppression of disease (p < 0.0001)
with only 10.88% loss in body weight and a maximum average clinical score of 2.42.
3.3. Study III - In vivo Efficacy of Novel MVBMOG/PLP in PLP-Induced EAE
The purpose of this study was to evaluate whether our novel peptide's efficacy in MOG-
induced EAE can be translated to PLP-induced EAE. Therefore, mice were given three s.c.
injections of MVBMOG/PLP, and its efficacy was compared to that of PBS. According to
clinical score data, MVBMOG/PLP suppressed disease significantly (p < 0.0001) while the
PBS-treated mice reached a maximal score of 1.67 and MVBMOG/PLP–treated mice reached
a maximum of 0.58 (Fig. 3A). The changes in body weight correlate exactly with the
observed differences in the clinical scores (p < 0.001), with PBS-treated mice losing 13.20%
of their body weight and MVBMOG/PLP–treated mice losing only a maximum of 4.66% (Fig.
3B).
3.4. In vitro Inflammatory Cytokine Production
Splenocytes from treated mice were isolated on day 30 and their cytokine production was
measured. EAE is an inflammatory disease characterized by high proliferation of
inflammatory TH1 and TH17 cells. In vitro cytokine studies can be used to indirectly
measure how strong the inflammatory response is in the mouse. The two key cytokine
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markers are IL-6 (Fig. 4A), which is important for TH1 and TH17 differentiation, and IFN-γ
(Fig. 4B), which is primarily a TH1 cytokine. The production of these pro-inflammatory
cytokines was lowest in the MVBMOG/PLP-treated mice and was signficantly different
compared to those treated with PBS (p < 0.01). MOG-BPI reduced IL-6 production and
significantly suppressed IFN-γ (p < 0.01). MVBMOG/PLP-treated mice had significantly
suppressed production of IL-6 compared to MOG-BPI-treated mice (p < 0.05) but only a
small difference in IFN-γ.
3.5. Splenocyte Proliferation
A proliferation assay was performed to evaluate the extent of responsiveness of splenocytes
from the different treatment groups to in vitro antigen stimulation. In addition, the cross-
reactivity of the antigens was studied. Splenocytes were isolated from PLP-immunized
SJL/J mice, and their proliferation was measured in non-immunized mice (no EAE) and
immunized mice treated with PBS, PLP-BPI, and MVBMOG/PLP. It was observed that the
responsiveness of PLP-BPI-treated mice was lower than in the PBS group when the
splenocytes were stimulated with PLP (p < 0.05). However, MVBMOG/PLP had the least
responsiveness when exposed to PLP. Finally, when the splenocytes were stimulated with
MOG, there was no difference in proliferation compared to the splenocytes stimulated with
medium. Therefore, the results indicated no cross-reactivity between PLP and MOG in PLP-
induced EAE (Fig. 5).
4. Discussion
BPI molecules have been developed to target many different antigens responsible for the
pathogenesis of autoimmune diseases. PLP-containing BPI molecules have been studied
extensively for the suppression of PLP-induced EAE (Kobayashi et al., 2007, Kobayashi et
al., 2008, Ridwan et al., 2010, Zhao et al., 2010). GAD-BPI was developed and was
successful in suppressing disease in the non-obese diabetic mouse model (Murray et al.,
2007). CII-BPI molecules composed of collagen-II antigenic peptides have been shown to
suppress collagen-II-induced rheumatoid arthritis in an animal model (unpublished data).
Our first goal for this study was to investigate whether BPI molecules composed of other
myelin sheath epitopes involved in EAE and MS can be developed to suppress disease.
Previously, only PLP-containing BPI molecules were tested. In this study, a novel BPI
molecule composed of the MOG antigen (MOG-BPI) was developed and tested in
suppressing EAE. While BPI molecules have demonstrated superior efficacy thus far, there
is a major limitation to their application. BPI molecules are antigen specific and, therefore,
will only suppress the immune response toward other antigens involved in the progression of
disease. In reality, MS patients have been shown to respond to many different epitopes
(Tuohy et al., 1997, Tuohy et al., 1999a, Tuohy et al., 1999b, Goebels et al., 2000, Muraro et
al., 2003), and single antigen-specific immunosuppression could have a disadvantage. Thus,
there is a need to expand this technology to target multiple antigens. For the first time, a
multivalent BPI molecule has been developed and its efficacy has been tested in two
separate EAE models. All in vivo results from the current study are summarized in Table 2.
The antigen specificity of BPI molecules has been previously demonstrated using BPI
molecules that contain scrambled and irrelevant peptides. In the irrelevant peptides, PLP
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peptide was replaced with ovalbumin (OVA326-337) and an epitope of virus capsid protein
(VP274-86) to produce OVA-BPI and VP2-BPI molecules (Kobayashi et al., 2007). OVA-
BPI and VP2-BPI had no or very low efficacy in suppressing EAE, while PLP-BPI had very
high efficacy at the same concentration as OVA-BPI and VP2-BPI (Kobayashi et al., 2007).
This result suggests that the efficacy of PLP-BPI is due to antigenic specificity of PLP-BPI,
and the observed residual efficacy of VP2-BPI is attributed to the cell adhesion peptide
LABL peptide in VP2-BPI (Kobayashi et al., 2007). The effect of linking PLP and LABL
peptides on efficacy of PLP-BPI was evaluated by comparing the efficacy of PLP-BPI and
unconjugated PLP and LABL. PLP-BPI had higher efficacy than a mixture of PLP and
LABL. However, the mixture of PLP and LABL had higher efficacy than PLP or LABL
peptide alone, suggesting that conjugation of the two peptides is important for efficacy
(Kobayashi et al., 2007). PLP-BPIsc with a scrambled PLP sequence also had no efficacy in
suppressing EAE, indicating antigenic specificity (Ridwan et al., 2010). Finally, the efficacy
comparison between a new molecule called PLP-cIBR and its derivative with a scrambled
PLP peptide (i.e., PLPsc-cIBR) showed that PLP-cIBR was very effective in suppressing
EAE while PLPsc-cIBR had no efficacy to suppress EAE (Kiptoo et al., 2013). In summary,
BPI molecules are significantly effective at suppressing EAE in an antigen-specific manner,
and conjugation between the antigenic peptide and the cell adhesion peptides (i.e., LABL or
cIBR peptide) has an important role in their action.
The in vivo efficacy and the potential cross-reactivity of MVBMOG/PLP, PLP-BPI and MOG-
BPI were evaluated in both PLP- and MOG-induced EAE. These models represent two
different disease states in MS. PLP-induced EAE is an animal model for relapsing-remitting
MS (RRMS) and MOG-stimulated EAE is an animal model for primary progressive MS
(PPMS). The differences between these two models are the lower severity of the disease in
PLP-induced EAE compared to that of MOG-induced EAE and the remitting-relapsing
disease course of the PLP-induced EAE. According to our studies, PLP-induced mice show
remission around day 25 and relapse around day 45 similar to RRMS while MOG-induced
EAE mice do not show any remission of the disease. The results showed that MVBMOG/PLP
suppressed the disease in both models. In PLP-induced mice, PLP-BPI suppressed the
disease while MOG-BPI did not, indicating that there was no cross-reactivity between these
two BPI molecules in PLP-stimulated EAE. This finding was well correlated with the
proliferation assay data showing that there was no response in splenocytes stimulated with
MOG. In contrast, a significant suppression of disease was observed with PLP-BPI in MOG-
stimulated EAE, thus suggesting some cross-reactivity of PLP-BPI in this model.
Interestingly, MVBMOG/PLP suppressed the disease better than MOG-BPI in MOG-induced
EAE, suggesting that there is an additive effect of potency when both antigenic peptides
(i.e., PLP and MOG) are conjugated in one molecule (i.e., MVBMOG/PLP). We propose that
the cross-reactivity of PLP-BPI and the better efficacy of MVBMOG/PLP than MOG-BPI in
MOG-induced EAE are caused by the ability of these BPI molecules to overcome epitope
spreading that includes PLP antigen. Due to the chronic and progressive nature of MOG-
induced EAE, the disease progression could cause the immune cells to become sensitive not
only to epitopes from MOG but also to PLP and/or MBP (i.e., antigenic spreading).
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A key factor in the progression of MS and EAE is a phenomenon known as epitope
spreading (Tuohy and Kinkel, 2000). Epitope spreading is believed to occur when there is
major tissue damage, and debris from the destroyed tissue is taken up, processed, and
presented by immune cells, leading to inflammatory response toward new epitopes
(Lehmann et al., 1993). During the course of the disease, T cells develop immunogenicity to
new myelin proteins. This causes further destruction that leads to chronic tissue damage of
the myelin sheath but, more importantly, it creates more difficulties in developing antigen-
specific therapies. Epitope spreading can occur intramolecularly, in which case some mice
develop autoreactivity toward MBP35-47, MBP81-100, and MBP121-140 over time when
MBP1-11 is the initiating antigen (Lehmann et al., 1992). In addition, there is evidence of
intermolecular epitope spreading where, during the course of the disease, proliferative
responses toward PLP are present in MBP-induced mice (Perry et al., 1991). There are no
reports in the literature of epitope spreading between MOG38-50 and PLP139-151, but we
believe that the efficacy of PLP-BPI in the MOG-induced model and the additive efficacy of
MVBMOG/PLP are possibly due to epitope spreading. We propose that MVBMOG/PLP
suppressed the T-cell response for MOG as well as PLP. This strategy of multi-antigenic
immunosuppression has been employed previously. Multi-antigenic peptide therapies made
of up four different antigens (PLP139-151, PLP178-191, MBP84-104, and MOG92-106) fixed to
splenic APC have been developed and have shown efficacy in suppressing EAE induced by
all four antigens (Smith and Miller, 2006).
BPI molecules are made up of two main components covalently linked to each other
(Manikwar et al., 2011). The first component is the antigenic peptide and the second is the
adhesion peptide. It is proposed that the antigenic peptide portion binds to the MHC-II
molecule on the surface of APC, and the adhesion peptide, which is derived from the LFA-1
protein, binds to ICAM-1, also on the surface of APC. Traditionally, we used a linker
composed of aminocaproic acid and glycine to link both peptide components in BPI
molecules. For the synthesis of MOG-BPI and MVBMOG/PLP, a polyethylene glycol-3
(PEG3) linker was used to improve solubility. Previously, we saw no significant difference
in the use of PEG3 or aminocaproic acid as a linker. We propose that, due to the presence of
the covalent linker, the BPI molecule tethers the loaded MHC-II molecule and ICAM-1, thus
hindering the formation of the immunological synapse. This prevents the initiation of an
inflammatory response to the specific antigen recognized by the MHC-II molecule. With the
MVB, the idea has been expanded to incorporate more than one antigenic peptide. It is
proposed that each antigenic peptide will be recognized by its respective MHC-II molecule
and will suppress the inflammatory response to that antigen.
MS and EAE are characterized by severe inflammation with high levels of IL-6 (Maimone
et al., 1997) and IFN-γ (Kebir et al., 2009) found in the CNS. Moreover, their role in the
pathogenesis of disease is significant. In addition to recruitment of other inflammatory
immune cells, IL-6 is a mediator in increasing the permeability of the BBB (Abbott et al.,
2006, Prendergast and Anderton, 2009), and IFN-γ has been reported to prevent
remyelination of the CNS (Lin et al., 2006). Therefore, in order to treat or suppress the
disease, therapies aimed at reducing the inflammatory response are vital. Currently on the
market, glatiramer acetate, a drug used for the treatment of MS, works by diverting the
immune response away from the TH1 phenotype (Neuhaus et al., 2001, Dhib-Jalbut, 2003).
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The cytokine data from the present study demonstrated that when MOG-BPI and
MVBMOG/PLP were administered to mice with MOG-induced EAE, the inflammatory
cytokines IL-6 and IFN-γ were suppressed significantly by both peptides, thus shifting the
balance away from the inflammatory response. In addition, the proliferation assay from
PLP-induced mice showed that PLP-BPI and MVBMOG/PLP significantly lowered the PLP-
responsive population of splenocytes.
PLP-BPI molecules have been shown to suppress the production of IL-17 in PLP-stimulated
EAE, implying that BPI molecules suppress the TH17 cell proliferation (Ridwan et al., 2010,
Badawi et al., 2012). In contrast, PLP-BPI stimulates the production of IL-10 (Ridwan et al.,
2010). The reduction of IL-6 has been shown to suppress the differentiation of TH17 and
TH1 phenotypes to protect against EAE development (Serada et al., 2008). PLP-BPI also
protects the CNS by inhibiting the breakdown of the BBB as measured by leakiness of the
BBB (Badawi et al., 2012). The leakiness was determined by measuring brain disposition of
Gadolinium-DTPA (Gd-DTPA) as determined by magnetic resonance imaging (MRI) after
its delivery in normal mice, diseased mice, and diseased mice treated with PLP-BPI. The
non-treated EAE-mice had the highest brain disposition of Gd-DTPA compared to normal
mice and PLP-BPI-treated EAE mice, while PLP-BPI-treated mice had Gd-DTPA brain
disposition similar to that in normal mice. This indicates that PLP-BPI can prevent the BBB
breakdown while suppressing EAE. In another study, a BPI molecule called PLP-cIBR
suppressed the demyelination in the CNS of EAE mice compared to PBS-treated mice
(Kiptoo et al., 2013).
Although MVBMOG/PLP has not been used to reverse EAE after the disease has progressed,
other PLP-BPI molecules have been shown to reverse the PLP-stimulated EAE disease. In
our previous study, PLP-BPI molecules were injected with a maximum of 3 injections (100
nmol/injection) after the animals showed disease scores of one or worse. The results showed
that BPI treatments produced faster remission of the disease than PBS treatment (Kobayashi
et al., 2008, Ridwan et al., 2010). In the future, a similar study will be carried out to compare
the efficacy of MVBMOG/PLP with that of other BPI molecules in reversing the disease after
it progresses; in addition, BPI molecules will be evaluated for preventing disease relapse in
the PLP-stimulated EAE model. Finally, the efficacy and mechanisms of action of
MVBMOG/PLP as a therapeutic vaccine will also be evaluated.
In conclusion, developing molecules that can target more than one epitope is critical for
making BPI technology more applicable for MS. In human disease, the identity of the
inciting antigen is not usually known. In addition, since the disease is frequently not
diagnosed early, other antigens of the myelin sheath become targeted by immune cells due
to epitope spreading. Therefore, molecules that can target many antigens are critically
important for the treatment of MS or EAE irrespective of the inciting antigens or antigenic
spread. Thus far, we have developed a peptide that is composed of two antigenic peptides.
For future studies, we would like to expand this peptide to incorporate other
immunodominant antigens to suppress disease initiated by other antigens as well as to avoid
the problem of intra- and inter-molecular epitope spreading.
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1. A novel peptide composed of MOG and an adhesion peptide was tested in EAE.
2. Another peptide composed of 2 myelin antigens and an adhesion peptide was
tested.
3. MOG-BPI suppressed disease significantly when tested in MOG-induced EAE.
4. MVPMOG/PLP was able to suppress both MOG- and PLP-induced EAE.
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In vivo cross-reactivity of MOG-BPI and PLP-BPI. PBS (100 μl) and peptides (100
nmol/100 μl) were administered s.c. on days 4, 7, and 10. MOG-BPI- and PLP-BPI-treated
mice were compared to PBS-treated mice in the MOG-induced EAE model and efficacy was
determined by (A) clinical disease score of EAE, expressed as the mean clinical score ±
SEM (n = 6), and (B) percent change in body weight, expressed as the mean % change in
body weight ± SEM (n = 6). The efficacy of MOG-BPI in suppressing disease in PLP-
induced EAE mice was determined using the (C) clinical disease score of EAE, expressed as
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the mean clinical score ± SEM (n = 6), and (D) percent change in body weight, expressed as
the mean % change in body weight ± SEM (n = 6).
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In vivo efficacies of MVBMOG/PLP and controls in suppressing MOG-induced EAE. PBS-
treated mice (n = 12) received s.c. injections of 100 μl PBS on days 4, 7, and 10. MOG- (n =
6), MOG-BPI- (n = 5), and MVBMOG/PLP- (n = 12) treated mice received 100 nmol/100 μl
PBS on days 4, 7, and 10 (s.c). The efficacy of each peptide was determined by (A) clinical
disease score of EAE, expressed as the mean clinical score ± SEM, and (B) percent change
in body weight, expressed as the mean % change in body weight ± SEM.
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In vivo efficacy of MVBMOG/PLP in suppressing PLP-induced EAE. MVBMOG/PLP-treated
mice (n = 6) received three s.c. injections at a concentration of 100 nmol/100 μl on days 4,
7, and 10 and its efficacy was compared to that of PBS in mice (n = 6) treated in a similar
fashion. Progress of the disease was monitored following (A) the clinical disease score,
expressed as the mean clinical score ± SEM, and (B) the percent change in body weight,
expressed as the mean % change in body weight ± SEM.
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Concentrations of pro-inflammatory cytokines (A) IL-6 and (B) IFN-γ from the cell culture
supernatant. Splenocytes were isolated from the spleens of MOG-induced EAE mice on day
30. The three different groups consisted of PBS-, MOG-BPI-, or MVBMOG/PLP- treated
mice on days 4, 7, and 10. The pooled splenocytes (n = 3 mice) were stimulated in vitro with
PLP139-151, and supernatant was isolated 72 hours later for cytokine detection (*p < 0.01).
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Incorporation of [3H] thymidine in splenocytes isolated from PLP-induced EAE mice on day
30. EAE-free mice were stimulated with ConA, medium, PLP (2 μM), or MOG (2 μM) and
the remaining treated groups were stimulated with only medium, PLP (2 μM), and MOG (2
μM). The three treatment groups consisted of PBS-, PLP-BPI-, or MVBMOG/PLP- treated
mice on days 4, 7, and 10. Each group (n = 3) was pulsed with [3H] thymidine 72 hours after
stimulation and incorporated radioactivity was measured the following day.
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Table 1
List of peptides used in the present study
Acp in the linker represents ε-aminocaproic acid. Ac- represents the acetyl-capped N-terminus of the peptide. -
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Table 2
Summary of in vivo studies
Groupa Induction antigen Incidence of diseaseb Mean maximal score ± SEM
In vivo Study I
PBS MOG 6/6 4.00 ± 0.18
PLP-BPI MOG 6/6 3.00 ± 0.47
MOG-BPI MOG 6/6 2.25 ± 0.46
PBS PLP 6/6 1.67 ± 0.59
MOG-BPI PLP 6/6 1.50 ± 0.53
In vivo Study II
PBS MOG 12/12 3.58 ± 0.24
MOG MOG 5/6 2.42 ± 0.52
MOG-BPI MOG 5/5 2.20 ± 0.31
MVBMOG/PLP MOG 4/12 0.88 ± 0.49
In vivo Study III
PBS PLP 6/6 1.67 ± 0.59
MVBMOG/PLP PLP 3/6 0.58 ± 0.27
a
All injections were administered s.c. at 100 nmol (100 μl PBS) on days 4, 7, and 10.
b
Incidence of disease was defined as a disease score of 1 or higher.
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